The series of novel
Introduction
Unknown 2-[(3-R-2-oxo-2H- [1, 2, 4] triazino [2,3-c] quinazolin-6-yl)thio]acetic acids and their amides were identified as compounds with antibacterial and antitumor activities as the result of chemistry and pharmacology researches [1] [2] [3] [4] . An important direction of further improvement of antitumor activity and expansion of the spectrum among such derivatives is a functionalization of amino substituents. We assume that the combination in one molecule as-triazino [2,3-c] quinazoline with thiazole, benzothiazole, and thiadiazole fragments, especially in the view of recent chemotherapy capacity, is one of the promising areas in the search for biologically active compounds with cytotoxic effects. Furthermore, that for these azoles and their derivatives, antibacterial [7, 9, 10, 13, 17, 24] , antifungal [10, 13] , antituberculous [6, 10] , anticancer [5, 8, 15, 16, 18, 19, 21, 22] , and other [11, 12, 14, 17, 20, 23, 31] activities are characteristic. So the introduction of «biophore» azole fragments in the structure of the «rigid» condensed heterocyclic system of as-triazino [2,3-c] quinazoline will likely lead to the change in direction and amplification of antitumor activity.
Results and Discussion

Chemistry
We selected the method of alkylation of potassium salts of 3-R-6-thio-6,7-dihydro-2H- [1, 2, 4] triazino [2,3-c] quinazolin-2-ones (1.1-1.4) by N-heteryl-2-chloroacetamides in dioxane or a dioxane-water mixture (2:1) due to the relatively low nucleophilic properties of the amino group of electron-deficient heterocycles (4-R-thiazolyl-2-, 6-R-1,3-benzothiazolyl-2-, 5-R-1,3,4-thiadiazolyl-2-amines) for the synthesis of N-(4-R-thiazolyl-2-, 6-R-1, 3-benzothiazol-2-yl, 5-R-1,3,4-thiazolyl-2-(3-R-2-oxo-2Н-[1,2,4] triazino [2,3-с] quinazolin-6-ylthio)acetamides (3.1-3.6 , 4.1-4.11, 5.1-5.9) (Sch. 1). The reaction has a short duration (60-90 minutes), a high yield of products (73.5-99.3%) , and a very high purity of the final reaction products. But as it turned out, the carbonyldiimidazole method of synthesis was thought that the corresponding acids 2.1-2.4 could be realized in the case of amides 3.1-3.3, 4.1, 4.2, 4.4-4.6, 4.9-4.11 (Sch. 1). The reaction was carried out by heating in DMF within 5-6 hours, but with resulting lower yields of the final products (62. 8-54.3%) . Moreover, the synthesized amides 3.1-3.3, 4.1, 4.2, 4.4-4.6, 4.9-4.11 required additional crystallization. -2-[(3-R-2-oxo-2H-[1,2,4] triazino [2,3-c] quinazolin-6-yl)thio]acetamides with thiazole and thiadiazole fragments.
The conducted preliminary studies of the antitumor activity permitted the obtainment of substantiated evidence of its presence among the relevant N- 2-[(3-R-2-оxо-2Н-[1,2,4] triazino [2,3-с] quinazolin-6-yl)thio]acetamides and it is important that these derivatives could be regarded as a structure of «potential» pharmacophore aniline fragments in this heterocyclic system [3] . Therefore, agents of combined 2-[(5-amino-1,3,4-thiadizol-2-yl) thio]-N-phenylacetamide and 2-[(3-R-2-оxо-2Н- [1, 2, 4] triazino [2,3-с] quinazolin -6-yl) thio]acetamide fragments, in our opinion, may become one of the most promising groups of organic compounds with antitumor activity. The relevant N-{5-[(2-(Ranilino)-2-oxоethyl)thio]-1,3,4-thiadiazole-2-yl}-2-chloroacetamides were synthesized by known methods, such as alkylation of 5-amino-1,3,4-thiadiazol-2-thiol by N-aryl-2-chloroacetamides in methanol, in the presence of sodium methoxide, followed by acylation of the formed products by 2-chloroacetyl chloride in dioxane in the presence of triethylamine. Alkylation of potassium salts 1.1 and 1.2 by N-{5-[ (2-(R-anilino)-2-oxоethyl) thio]-1,3,4-thiadiazol-2-yl}-2-chloroacetamides was carried out in dioxane, refluxing for 90-120 min (Sch. 2), forming individual compounds with high yields 6.1-6.5 67.7-94.8%. -2-[(3-R-2-oxo-2H-[1,2,4] triazino [2,3-c] quinazolin-6-yl)thio]acetamides with 2-S-substituted 2-thiothiadiazole fragments.
Sch. 2. Synthesis of N-R
The identity of the synthesized compounds was confirmed by LC-MS (APCI), elemental analysis, IR, 1 H, 13 C NMR, and MS. The chromato-mass study of the synthesized compounds 3.1-3.6, 4.1-4.11, 5.1-5.9, 6.1-6.5 in a "soft" ionization (chemical ionization at atmospheric pressure) allowed each in each case to register the molecular ion peak [M+1] in high intensity. In addition, the characteristic ion [M+3] was present in the majority of compounds, which characterized the presence of the sulfur isotope in the molecule.
Characteristic vibrations of the ν NН -group at 3325-3008 cm −1 , ν СО -group (bond «Amide I») at 1841-1659 cm −1 , and the bond of combined stretchings and deformations of the N-H and C-N bonds («Amide II») at 1630-1556 cm −1 were observed in the IR spectra of compounds 3.1-3.6, 4.1-4.11, 5.1-5.9, 6.1-6.5. Vibrations of the carbonyl group in the triazinoquinazoline cycle appeared at 1684-1645 cm −1 , and a characteristic outline of low intensity vibrations of the ν -С=С-fragment of aromatic rings appeared at 1589-1468 cm −1 , vibrations of the aromatic C-C bond at 1520 cm −1 and 1449 cm −1 , out-of-plane vibrations γ (=С-Н) at 850-666 cm −1 , and intensive vibrations at 2992-2829 cm −1 , that are related to the symmetric and antisymmetric stretchings of the ν СH3 -and ν СH2 -groups.
The wide signal of the amide proton in the 1 H NMR spectra for heterylamides 3.1-3.6, 4.1-4.11, 5.1-5.9 was observed in a weak field at 13.09-12.46 ppm. Two broad singlets of the proton of the NHCO-group of the relevant diamides 6.1-6.5 were recorded at 13.88-10.12 ppm and 13.88-13.14 ppm, the latter one was the most deshielded, located near the electron-deficient thiadiazole cycle. The two-proton singlet of the SCH 2 -group acetamides (3.1-3.6, 4.1-4.11, 5.1-5.9) was observed at 4.45-4.04 ppm and the protons of this functional group in diamides 6.1-6.5 appeared as singlets at 4.27-4.21 ppm and 4.38-4.34 ppm. The as-triazino [2,3-c] quinazoline system in the 1 H-NMR spectra of compounds 3.1-3.6, 4.1-4.11, 5.1-5.9, 6.1-6.5 was characterized by the subspectra signals of the protons АВCD-system: two doublet signals of the protons H-11 (8.50-8.38 ppm) and H-8 (7.62-7.21 ppm) and two triplet signals of the protons H-9 (7.94-7.83 ppm) and H-10 (7.70-7.30 ppm) . It is important to note that the doublet H-8 and triplet H-9 mostly resonated together as a multiplet at 7.69-7.58 ppm and sometimes with aromatic protons of the substituent at position 3 (compounds 3.2, 3.5, 3.6, 4.2, 4.6, 4.8, 4.11, 5.2, 5.7, 6.1, 6.3, 6.5) or the heterocyclic fragment (compounds 3.5, 3.6, 5.2, 5.3-5.5). In the 1 H-NMR spectra of amides 3.1-3.4 signals of the protons of the thiazole cycle resonated as doublets at 7.23-7.21 ppm (H-5) and 7.53-7.51 ppm (H-4) . The singlet proton in position 5 of the thiadiazole system of amides 4.1-4.4 was observed at 9.18-8.82 ppm. In addition, the 1 H-NMR spectra of the synthesized compounds was characterized by a set of signals of protons of aromatic substituents at position 4 of thiazole (compounds 3.5, 3.6), position 3 of the [1, 2, 4] triazino [2,3-c] (4.5-4.11) and position 6 of the 1,3-benzothiazole cycle (5.1-5.5) . These protons, depending on the surroundings, have an appropriate multiplicity [3] .
A «classical» chemical shift of carbon atoms of the -S-CH 2 -group in the 13 28-35.23 ppm and 38.13-38.12 ppm. This aspect clearly confirms the S-regioselectivity of the reaction. In addition, the low magnetic field deshielded the carbon atom of the -CONH-group and carbons at the 2 and 6 positions of the [1, 2, 4] triazino [2,3-c] , [Heteryl-S] +• was associated with the same process, namely, the degradation of the as-triazinoquinazoline system on the C(2)-C(3) and N(3)-N(4), and formation of highly stable ions with m/z 244 (9.10-100.0%), m/z 216 (100-50.1%), and m/z 203 (11.3-33 .9%), respectively. The formed fragmentary ions eliminated fragments S, SCH 2 , СО, СNS, and CNO forming the ions m/z 187, 174, 170, 144, 143, and 142 of various intensities in the spectra.
In the mass spectra of diamide 6.2, no molecular ion was observed as it is an unstable compound. 
Pharmacology
Bioluminescence inhibition test
In the first stage, we researched the cytotoxicity of the synthesized compounds by the bioluminescent test of the luminescent bacteria Photobacterium leiognathi Sh1 ( 
Tab. 1.
Bioluminescence inhibiting assay data, %
The SAR study revealed that: ,2,4] triazino [2,3-c] quinazolin-6-yl)-thio]acetic acids with a thiazolamide fragment exhibited a high cytostatic effect against the luminescent bacteria Photobacterium leiognathi Sh1;  a cytostatic effect of the synthesized compounds was retained with the replacement of thiazolamide by benzothiazole or thiadiazolamide fragments in the molecule,  the replacement of the methyl group in position 3 of the triazino [2,3-c] quinazoline cycle by aryl function in most cases was the reason for the increased cytotoxic action,  the replacement of the methyl group in position 6 in the benzothiazolamide fragment by the methoxygroup or chlorine didn't lead to the loss of cytostatic action, and  the introduction of a butyl substituent in position 5 of the thiadiazolamide fragment resulted in the initiation of growth of the luminescent bacteria Photobacterium leiognathi Sh1.
Thus, high levels of growth inhibition and cytotoxicity of compounds to the bacteria P. leiognathi Sh1 served as a prerequisite for further research on their antitumor activity.
Anticancer assay for preliminary in vitro testing
The synthesized N-R-2-[(3-R-2-oxo-2H
- [1, 2, 4] triazino [2,3-c] quinazolin-6-yl)thio]acetamides with thiazole and thiadiazole fragments in the molecules (3.1-3.6, 4.1-4.11, 5.1-5.9, 6.1-6.5) were submitted and evaluated at the single concentration of 10 μM in the panel of approximately 60 cancer cell lines. The human tumor cell lines were derived from nine different cancer types: leukemia, melanoma, lung, colon, CNS, ovarian, renal, prostate, and breast cancers. Primary anticancer assays were performed according to the US NCI protocol, which was described elsewhere (see e.g. http://dtp.nci.nih.gov) [29] [30] [31] . The results of primary screening are reported as the percent cancer cell line growth (GP%) and are presented in Table 2 . The range of growth % shows the lowest and the highest growth % found among the different cancer cell lines.
The conducted screening studies of compounds at a concentration of 10 μM showed that the compounds 3.1, 3.2, 6.5 turned to be effective against most cancer cell lines (Table 2) . Thus, N- (1,3-thiazol-2-yl)-2-[(3-methyl-2-oxo-2H-[1,2,4] triazino [2,3-c] quinazolin-6-yl)thio]-acetamide (3.1) showed high cytotoxic activity against 57 cell lines (inhibition of growth by 30-100%). Replacement of the methyl substituent at position 3 (compound 3.1) of the triazinoquinazoline cycle by phenyl (3.2) and 4-methoxyphenyl (3.4) substituents led to a decrease in cytotoxicity against most cancer cell lines ( Table 2) . Modifications of the molecule by replacing the thiazole cycle ( Further dose-dependent activity was investigated for the most effective compounds 3.1, 3.2, and 6.5 according to the standard NCI procedure for the 57-59 lines of nine types of cancer at five concentrations at 10-multiply dilution (100 μM, 10 μM, 1 μM, 0.1 μM, and 0.01 μM). In the experimental result, the three dose-dependent parameters were calculated: 1) GI 50 -molar concentration of the compound that inhibits 50% net cell growth; 2) TGI -molar concentration of the compound leading to a total inhibition of cell growth; 3) LC 50 -molar concentration of the compound leading to 50% net cell death. Furthermore, the mean graph midpoints (MG_MID) were calculated for each of the parameters, giving an average activity parameter over all of the cell lines for the tested compounds. For the calculation of the MG_MID, insensitive cell lines were included with the highest concentration tested (Table 3) .
Among the studied substances, compound 3.1 showed the highest activity and broad spectrum with an average value of effective level of inhibition of growth of cell lines (MG_MID GI 50 = 6.47 μМ). The SAR study revealed that:
acids with a thiazolamide fragment demonstrated high antitumor activity,  the replacement of thiazolamide by benzothiazole or thiadiazolamide fragments leed to a significant loss in antitumor activity,  the replacement of the methyl group in position 3 of the triazino [2,3-c] quinazoline cycle by the phenyl, 4-methylphenyl, or 4-methoxyphenyl group caused the modest increase in activity against some cancer cell lines,  the replacement of the methyl group at position 6 of the benzothiazolamide fragment by methoxygroup or chlorine didn't lead to a significant increase in activity,  the introduction of the butyl substituent in position 5 of the thiadiazolamide fragment was the reason for a slight increase in activity against some cancer cell lines, and  the combination of one molecule of 2-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-Nphenylacetamide and 2-[(3-R-2-oxo-2H- [1, 2, 4] triazino [2,3-c] quinazolin-6-yl)thio]-acetamide fragments leed to a high level of antitumor activity and requires further study.
Conclusion
In the present paper, 31 new N-R-2-[(3-R-2-oxo-2H-[1,2,4] triazino [2,3-c] 
μM). The further modification of 2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazolin-6-yl)thio]acetic acid
by broadening the base of amides is indisputably interesting and is being considered, which will be the premise for the creation of more effective anticancer agents among the barely known heterocyclic system.
Experimental
Chemistry
Melting points were determined in open capillary tubes and were uncorrected. The elemental analyses (C, H, N, S) were performed using the ELEMENTAR vario EL cube analyzer (USA). Analyses were indicated by the symbols of the elements or functions within ±0.3% of the theoretical values. The IR spectra (4000-600 cm -1 ) were recorded on a Bruker ALPHA FT-IR spectrometer (Bruker Bioscience, Germany) using a module for measuring attenuated total reflection (ATR). The 1 H NMR spectra (400 MHz) and 13 C NMR spectra (100 MHz): were recorded on the Varian-Mercury 400 (Varian Inc., Palo Alto, CA, USA) spectrometer with TMS as the internal standard in DMSO-d 6 solution. LC-MS were recorded using the chromatography / mass spectrometric system which consists of high performance liquid chromatograph «Agilent 1100 Series» (Agilent, Palo Alto, CA, USA) equipped with a diode-matrix and mass-selective detector «Agilent LC/MSD SL» (atmospheric pressure chemical ionization -APCI). The electron impact mass spectra (EI-MS) were recorded on the Varian 1200 L instrument at 70 eV (Varian, USA). The purity of all obtained compounds was checked by 1 H-NMR and LC-MS. Substances 1.1-1.4 and 2.1-2.4 were synthesized according to the reported procedures [1] [2] [3] . Other starting materials and solvents were obtained from commercially available sources and used without additional purification. 1   -1,3-thiazolyl-2-)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazolin-6-yl)thio]acetamides (3.1-3.6) Method A N- (4-R-1,3-thiazol-2-yl )-2-chloroacetamide (0.011 mol) was added to a suspension of potassium salt of 3-R-6-thio-6,7-dihydro-2Н- [1, 2, 4] triazino [2,3-с] quinazolin-2-ones (2.1-2.4) (0.01 mol) in 20 ml of dioxane or water-dioxane (1:2) and refluxed for 60-90 minutes. The mixture was cooled and poured into the water. The precipitate was filtered, dried, and recrystallized from the DMF-water (1:1).
General procedure for the synthesis of N-(4-R
Method B
N,N'-carbonyldiimidazole (1.95 g, 0.011 mol) was added to a solution of proper acid (2.1-2.4) (0.01 mol) in 10 ml of anhydrous DMF and heated in the water bath at 60-80°С for 1 hour with a calcium chloride tube. The proper 4-R-1,3-thiazolyl-2-аmines (0.01 mol) were added with stirring to the resulting mixture and refluxed for 5-6 hours. The mixture was poured into the water, and neutralized to pH 6-7 by acetic acid. The precipitate was filtered, dried, and recrystallized from the DMF-water (1:1).
2-[(3-Methyl-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazolin-6-yl)thio]-N-(1,3-thiazol-2-yl)acetamide (3.1)
Yield: Method А, 79.3%; Method B, 61.3%; M.p. 280-282°C; IR (cm -1 ): 3166, 3121, 3093, 3068, 2954, 2910, 2820, 2726, 1678, 1668, 1590, 1559, 1512, 1469, 1425, 1376, 1359, 1328, 1282, 1261, 1206, 1177, 1136, 1120, 1056, 1042, 952, 873, 849, 804, 773, 733, 712, 701, 684 [1, 2, 4] triazino [2,3-c] 
2-[(2-Oxo-3-phenyl-2H-
quinazolin-6-yl)thio]-N-(1,3-thiazol-2-yl)acetamide (3.2)
Yield: Method А, 83.9%; Method B, 58.2%; M.p. 264-266°C; IR (cm -1 ): 3173, 3091, 3063, 2921, 2793, 2691, 1696, 1667, 1583, 1563, 1555, 1503, 1486, 1467, 1442, 1396, 1370, 1342, 1326, 1314, 1282, 1260, 1239, 1162, 1132, 1074, 985, 965, 938, 873, 848, 812, 770, 755, 719, 694, 685, 651 (25.4), 144 (14.8), 143 (41.9), 142 (23.2), 140 (6.2), 127 (20.1), 126 (11.4), 116 (5.3), 113 (9.3), 104 (6.6), 103 (10.6), 90 (6.9) , 88 (5.1), 77 (16.6), 76 (41.5), 75 (11.9) , 73 (7.3), 63 (6.5), 60 (6.7), 58 (22.4) , 57 (6.0), 55 (11.4) , 51 (7.5) , 50 (7.0), 47 (10.4) 3.16; N, 18.82; S, 14.36; Found: C, 56.49; Н, 3.16; N, 18.82; S, 14. 36. [1, 2, 4] triazino [2,3-c] quinazolin -6-yl] thio}-N- (1,3-thiazol-2-yl) acetamide (3.3) Yield: Method А, 81.4%; Method B, 54.8%; M.p. 274-275°C; IR (cm -1 ): 3243, 3183, 3115, 3066, 3008, 2980, 2942, 2867, 2802, 2700, 1683, 1660, 1626, 1583, 1546, 1514, 1485, 1469, 1395, 1366, 1328, 1263, 1236, 1172, 1155, 1137, 1104, 1066, 1021, 986, 971, 937, 905, 874, 851, 835, 818, 778, 765, 715, 701, 685, 677, 638, 624, 605; 1 H-NMR (400 MHz) δ: 2.42 (s, 3Н, 3-(4-CH 3 Ph)), 4.36 (s, 2Н, -S-CH 2 ), 7.23 (d, 1Н, J=3.6, 7.41 (d, 2Н, J=8.3, Ph)), 7.52 (d, 1Н, J=3.6, 7.61 (d, 1Н, J=7.9, 7.67 (t, 1Н, J=7.7, 7.94 (t, 1Н, J=7.7, 8.25 (d, 2Н, J=8.3, ), 8.47 (d, 1Н, J=7.9, Н-11) 3.50; N, 18.25; S, 13.92; Found: C, 57.37; Н, 3.49; N, 18.25; S, 13. 90. [1, 2, 4] triazino [2,3-c] quinazolin -6-yl] thio}-N- (1,3-thiazol-2-yl) acetamide (3.4) Yield: Method А, 73.5%; M.p. 276-280°C; IR (cm -1 ): 3219, 3204, 3116, 3073, 3008, 2929, 2835, 2803, 2708, 1682, 1665, 1630, 1596, 1581, 1557, 1538, 1487, 1470, 1439, 1414, 1392, 1368, 1331, 1305, 1254, 1237, 1173, 1137, 1118, 1104, 1066, 1013, 986, 973, 938, 908, 873, 852, 819, 780, 763, 722, 697, 682, 624; 1 H-NMR (400 MHz) δ: 3.87 (s, 3Н, 4-CH 3 OPh), 4.37 (s, 2Н, -S-CH 2 ), 7.16 (d, 2Н, J=8.8, OРh), 7.23 (d, 1Н, J=3.6, 7.53 (d, 1Н, J=3.6, 7.62 (d, 1Н, J=7.9, 7.66 (t, 1Н, J=7.7, 7.93 (t, 1Н, J=7.7, 8.38 (d, 2Н, J=8.8, OРh), 8.46 (d, 1Н, J=7.9, Н-11) 3.38; N, 17.64; S, 13.46; Found: C, 55.43; Н, 3.36; N, 17.64; S, 2, 4] triazino [2,3-c] (4-phenyl-1,3-thiazol-2-yl) acetamide (3.5) .
2-{[3-(4-Methylphenyl)-2-oxo-2H-
2-{[3-(4-Methoxyphenyl)-2-oxo-2H-
quinazolin-6-yl)thio]-N-
Yield: Method А, 88.5%; M.p. 265-267°C; IR (cm -1 ): 3584, 3172, 3057, 2972, 2927, 2866, 1692, 1666, 1651, 1626, 1586, 1565, 1550, 1503, 1484, 1470, 1443, 1369, 1322, 1311, 1286, 1267, 1247, 1183, 1156, 1137, 1105, 1072, 1061, 1026, 1001, 991, 942, 914, 904, 887, 873, 849, 813, 771, 756, 729, 718, 690, 673, 655; 1 H-NMR (400 MHz) δ: 4.40 (s, 2Н, -S-СН 2 -), 7.35 (t, 1Н, J=7.5, 7.46 (t, 2Н, J=7.5, 6Н, 4', 10), 3Н, 8.31 (d, 2Н, J=7.3, 8.48 (d, 1Н, J=7.9, 3.47; N, 16.08; S, 12.27; Found: C, 62.05; Н, 3.47; N, 16.08; S, 12. 27. [1, 2, 4] triazino [2,3-c] quinazolin -6-yl] thio}-N- (4-phenyl-1,3-thiazol-2-yl) acetamide (3.6) .
2-{[3-(4-Methoxyphenyl)-2-oxo-2H-
Yield: Method А, 76.3%; M.p. 258-260°C; IR (cm -1 ): 3332, 3174, 3067, 2970, 2837, 1696, 1684, 1650, 1589, 1553, 1537, 1491, 1469, 1444, 1419, 1365, 1341, 1320, 1288, 1258, 1175, 1151, 1138, 1119, 1074, 1029, 990, 975, 941, 904, 841, 771, 763, 728, 716, 687, 657, 642, 613; 1 H-NMR (400 MHz) δ: 3.87 (s, 3H, OPh)), 4.39 (s, 2Н, -S-СН 2 -), 7.17 (d, 2Н, J=8.9, OPh)), 7.36 (t, 1Н, J=7.5, 7.46 (t, 2Н, J=7.5, 3Н, 10), 3Н, 8.39 (d, 2Н, J=8.9, OPh)), 8.46 (d, 1Н, J=7.9, Н-11) 3.65; N, 15.21; S, 11.60; Found: C, 60.86; Н, 3.65; N, 15.21; S, 11.60 . were added with stirring to the resulting mixture and refluxed for 5-6 hours. The mixture was poured into the water, and neutralized to pH 6-7 by acetic acid. The precipitate was filtered, dried, and recrystallized from the DMF-water (1:1). [1, 2, 4] triazino [2,3-c] quinazolin-6-yl)thio]-N- (1,3,4-thiadiazol-2-yl) ): 3153, 3104, 2905, 2826, 2711, 1701, 1659, 1587, 1556, 1509, 1466, 1434, 1382, 1365, 1323, 1285, 1261, 1214, 1190, 1160, 1129, 1103, 1045, 953, 906, 887, 872, 826, 805, 776, 717, 700, 686, 672, 630, 605; 1 H-NMR (400 MHz) δ: 2.40 (t, 3Н, 3-СН 3 ), 4.37 (s, 2Н, -S-CH 2 ), 7.56 (d, 1Н, J=7.9, Н-8), 7.65 (t, 1Н, J=7.7, Н-10), 7.92 (t, 1Н, J=7.7, Н-9), 8.45 (d, 1Н, J=7.9, Н-11) , 2.88; N, 25.44; S, 16.64; Found: C, 46.72; Н, 2.91; N, 25.47; S, 2, 4] triazino [2,3-c] quinazolin-6-yl)thio]-N- (1,3,4-thiadiazol-2-yl) acetamide (4.2) Yield: Method А, 89.4%; Method B, 53.3%; M.p. 295-297°C; IR (cm -1 ): 3173, 3055, 2952, 2904, 2838, 2728, 1706, 1675, 1595, 1566, 1554, 1510, 1488, 1470, 1446, 1358, 1326, 1315, 1287, 1270, 1242, 1183, 1168, 1139, 1119, 1103, 1081, 1050, 990, 959, 941, 903, 886, 872, 840, 812, 783, 771, 753, 710, 690, 653 [1, 2, 4] triazino [2,3-c] quinazolin -6-yl] thio}-N- (1,3,4-thiadiazol-2-yl) acetamide (4.3) Yield: Method А, 84.5%; M.p. 292-294°C; IR (cm -1 ): 3170, 3057, 2952, 2899, 2831, 2728, 1705, 1672, 1594, 1565, 1551, 1504, 1468, 1450, 1413, 1361, 1328, 1308, 1285, 1272, 1240, 1183, 1169, 1152, 1138, 1118, 1104, 1074, 1051, 1020, 990, 959, 940, 906, 872, 831, 816, 782, 770, 714, 703, 685, 641, 628, 603; 1 H-NMR (400 MHz) δ: 2.06 (s, 3Н, 3-(4-СН 3 Ph)), 4.04 (s, 2Н, -S-CH 2 ), 7.05 (d, 2Н, J=7.9, Ph)), 7.21 (d, 1Н, J=7.9, Н-8), 7.30 (t, 1Н, J=7.7, Н-10), 7.57 (t, 1Н, J=7.7, H-9), 7.88 (d, 2Н, J=7.9, Н-2', 6' 3-(4-СН 3 Ph)), 8.45 (d, 1Н, J=7.9, 8.82 (с, 1Н, 3.28; N, 21.24; S, 13.89; Found: C, 54.65; Н, 3.28; N, 21.24; S, 13. 89. [1, 2, 4] triazino [2,3-c] quinazolin -6-yl] thio}-N- (1,3,4-thiadiazol-2-yl) acetamide (4.4) Yield: Method А, 78.5%; Method B, 55.9%; M.p. 304-306°C; IR (cm -1 ): 3050, 3011, 2952 , 2912 , 2833 , 2728 , 1713 , 1663 , 1590 , 1563 , 1545 , 1497 , 1468 , 1454 , 1422 , 1360 , 1341 , 1329 , 1320 , 1288 , 1274 , 1260 , 1241 , 1170 , 1155 , 1139 , 1116 , 1052 , 1021 1 H-NMR (400 MHz) δ: 3.87 (s, 3Н, 3-(4-СН 3 ОPh)), 4.40 (s, 2Н, -S-CH 2 ), 7.16 (d, 2Н, J=8.7, OPh)), 7.55 (d, 1Н, J=7.9, H-8), 7.66 (t, 1Н, J=7.7, Н-10), 7.93 (t, 1Н, J=7.7, Н-9), 8.38 (d, 2Н, J=8.7, 2', 6' 3-(4-СН 3 ОPh)), 8.46 (d, 1Н, J=7.9, 9.17 (s, 1Н, 3.17; N, 20.53; S, 13.43; Found: C, 52.82; Н, 3.17; N, 20.53; S, 2, 4] triazino [2,3-c] quinazolin-6-yl)thio]-N- (5-propyl-1,3,4-thiadiazol-2-yl) acetamide (4.5) Yield: Method А, 90.1%; Method B, 59, 3%; ): 2962, 2910, 2835, 2727, 1703, 1664, 1587, 1557, 1508, 1469, 1426, 1360, 1336, 1284, 1265, 1240, 1198, 1183, 1169, 1137, 1120, 1108, 1044, 954, 873, 838, 778, 713, 701, 689, 674, 630, 7.55 (d, 1Н, J=7.9, Н-8), 7.64 (t, 1Н, J=7.7, Н-10), 7.92 (t, 1Н, J=7.7, Н-9), 8.44 (d, 1Н, J=7.9, Н-11), 12.89 (s, 1Н, -С(О) 4.01; N, 22.93; S, 15.00; Found: C, 50.57; Н, 4.01; N, 22.93; S, 2, 4] triazino [2,3-c] quinazolin-6-yl)thio]-N- (5-propyl-1,3,4-thiadiazol-2-yl) acetamide (4.6) Yield: Method А, 93.9%; Method B, 54.3%; M.p. 244-246°C; IR (cm -1 ): 2964, 2868, 2727, 1696, 1671, 1589, 1562, 1509, 1488, 1468, 1445, 1381, 1337, 1312, 1283, 1269, 1241, 1172, 1136, 986, 965, 939, 873, 833, 811, 780, 767, 751, 706, 686, 652 4Н, 4', 7.67 (t, 1Н, J=7.7, 7.94 (t, 1Н, J=7.7, 8.29 (d, 2Н, J=7.3, 2', 8.48 (d, 1Н, J=7.9, (8), 126.67 (10), 128.19 (4' Ph, 11), 128.96 (3', 5' Ph), 129.82 (2', 6' Ph), 132.08 (1' Ph), 136.11 (9), 144.06 (3), 149.76 (11b), 151.09 (2' Thiadiazol), 154.53 (7а), 158.75 (5' Thiadiazol), 6), 160.14 (6), 164.63 (2) , 167.25 (СОNH); EI-MS, m/z (I rel , %) = 489 (1.4), 353 (5.5), 347 (5.4), 320 (7.6), 313 (8.6), 293 (5.0), 284 (5.4), 244 (10.8), 219 (5.7) , 218 (14.1), 217 (67.1), 216 (33.8), 215 (9.5), 203 (11.3), 191 (10.9), 190 (5.0), 189 (23.6), 188 (10.1), 187 (8.3), 186 (15.8), 185 (28.0), 171 (14.9), 170 (57.1), 161 (24.2), 160 (14.7), 159 (6.0), 157 (24.6), 156 (6.1), 154 (19.9), 148 (7.2), 145 (16.9), 144 (12.0), 143 (17.4), 142 (7.4), 141 (18.9), 134 (5.7), 131 (6.3), 130 (10.6), 129 (30.9), 128 (41.3), 127 (5.5), 117 (10.7), 116 (12.5), 115 (82.2), 114 (11.8), 104 (6.9) , 103 (100.0), 101 (21.5), 101 (11.8) , 100 (16.5), 99 (5.9) , 97 (5.5), 95 (5.0), 91 (13.2), 90 (23.2), 89 (9.6), 88 (6.3), 87 (12.2), 86 (15.8), 85 (5.7) , 84 (7.8), 77 (6.5), 76 (30.7), 74 (40.8), 73 (12.3), 72 (19.8), 71 (14.5), 70 (22.2), 69 (30.1), 68 (9.9), 67 (6.4), 66 (6.1), 65 (9.5), 64 (32.1), 63 (29.2), 62 (15.3), 61 (12.9), 60 (63.8), 59 (40.5), 58 (24.1), 57 (7.8), 56 (8.6), 55 (9.2), 54 (9.3) , 53 (7.3), 52 (8.4), 51 (9.0), 47 (15.3), 46 (13.5), 45 (40.0), 43 (29.0), 42 (5.8), 41 (10.8), 40 (7.9) , 56.43; Н, 3.91; N, 20.03; S, 13.10; Found: C, 56.43; Н, 3.92; N, 20.04; S, 3, 2, 4] triazino [2,3-c] quinazolin-6-yl)thio]acetamide (4.7) Yield: Method А, 73.6%; M.p. 234-236°C; IR (cm -1 ): 2956, 2924, 2857, 2738, 1690, 1671, 1589, 1557, 1508, 1488, 1468, 1447, 1383, 1330, 1314, 1285, 1271, 1243, 1168, 1134, 1102, 1002, 986, 969, 938, 877, 834, 810, 770, 753, 720, 705, 688, 653 7.55 (d, 1Н, J=7.9, H-8), 7.64 (t, 1Н, J=7.7, H-10), 7.92 (t, 1Н, J=7.7, Н-9), 8.43 (d, 1Н, J=7.9, Н-11) 4.34; N, 22.21; S, 14.52; Found: C, 51.68; Н, 4.33; N, 22.20; S, 3, 2, 4] triazino [2,3-c] 2956, 2924, 2857, 2738, 1690, 1671, 1589, 1557, 1508, 1488, 1468, 1447, 1383, 1330, 1314, 1285, 1271, 1243, 1168, 1134, 1102, 1002, 986, 969, 938, 877, 834, 810, 770, 753, 720, 705, 688, 653 5Н, 4', 7.94 (t, 1Н, J=7.7, 8.29 (t, 2Н, J=7.3, 2', 8.48 (d, 1Н, J=7.9, 4.20; N, 19.47; S, 12.73; Found: C, 57.24; Н, 4.20; N, 19.47; S, 3, 2, 4] triazino [2,3-c] quinazolin -6-yl] thio}acetamide (4.9) Yield: Method А, 74.4%; Method B, 56.8%; M.p. 262-265°C; IR (cm -1 ): 3244, 3078, 2955, 2914, 2856, 2725, 1696, 1674, 1624, 1609, 1588, 1565, 1548, 1515, 1503, 1486, 1468, 1417, 1376, 1331, 1309, 1274, 1241, 1184, 1165, 1137, 1106, 1072, 1021, 988, 966, 939, 902, 867, 856, 835, 826, 807, 780, 772, 755, 711, 701, 685, 626 7.40 (d, 2Н, J=7.9, Н-3', 5',3-(4-СН 3 Ph)), 7.58 (d, 1Н, J=7.9, H-8), 7.66 (t, 1Н, J=7.7, H-10), 7.93 (t, 1Н, J=7.7, Н-9), 8.24 (t, 2Н, J=7.9, 2', 6' 3-(4-СН 3 Ph)), 8.46 (d, 1Н, J=7.9, Н-11) 4.48; N, 18.94; S, 12.39; Found: C, 57.98; Н, 4.47; N, 18.97; S, 3, 2, 4] triazino [2,3-c] 3066, 2961, 2920, 2859, 2712, 1692, 1662, 1622, 1589, 1563, 1503, 1468, 1423, 1382, 1361, 1325, 1283, 1259, 1205, 1166, 1133, 1120, 1043, 1018, 1001, 956, 872, 840, 780, 724, 687, 630 7.54 (d, 1Н, J=7.9, Н-8), 7.64 (t, 1Н, J=7.7, Н-10), 7.91 (t, 1Н, J=7.7, Н-9), 8.43 (d, 1Н, J=7.9, Н-11) 4.34; N, 22.21; S, 14.52; Found: C, 51.71; Н, 4.36; N, 22.23; S, 3, 2, 4] triazino [2,3-c] 3263, 3198, 3063, 2956, 2923, 2853, 1702, 1665, 1588, 1550, 1502, 1485, 1466, 1443, 1367, 1337, 1312, 1286, 1268, 1252, 1242, 1183, 1157, 1137, 1117, 1081, 1049, 1001, 989, 957, 940, 888, 870, 847, 812, 786, 773, 756, 692, 655, 5Н, 4', 7.94 (t, 1Н, J=7.7, 8.29 (t, 2Н, J=7.3, 2', 8.48 (d, 1Н, J=7.9, 4.20; N, 19.47; S, 12.73; Found: C, 57.23; Н, 4.19; N, 19.45; S, 12.70 . 
2-[(3-Methyl-2-oxo-2H-
2-{[3-(4-Methylphenyl)-2-oxo-2H-
2-{[3-(4-Methoxyphenyl)-2-oxo-2H-
N-(6-R
1 -1,3-benzothiazol-2-yl)-2-chloroacetamides (0.011 mol) were added to a suspension of potassium salt of 3-R-6-thio-6,7-dihydro-2Н- [1, 2, 4] triazino [2,3-с] quinazolin-2-ones (1.1-1.4) (0.01 mol) in 20 ml of dioxane (5.6-5.9) or water-dioxane (1:2) (5.1-5.5) and refluxed for 60-90 minutes. The mixture was cooled and poured into the water. The precipitate was filtered, dried, and recrystallized from the DMF-water (1:1) . N- 2, 4] triazino [2,3-c] 3193, 3155, 3066, 2991, 2963, 2923, 2862, 1697, 1661, 1587, 1555, 1504, 1470, 1455, 1388, 1357, 1312, 1283, 1257, 1229, 1205, 1161, 1135, 1108, 1078, 1041, 989, 952, 898, 887, 868, 821, 803, 789, 777, 743, 699, 686, 672, 658, 630, 616; 1 H-NMR (400 MHz) δ: 2.40 (s, 6Н, 3-CH 3 ; 6-CH 3 ), 4.37 (s, 2Н, -S-CH 2 ), 7.27 (d, 1Н, J=8.3, 2Н, 10), 7.88 (d, 1Н, J=8.3, 7.74 (s, 1Н, 7.90 (t, 1Н, J=7.7, 8.44 (d, 1Н, J=7.9, 24; Н, 3.60; N, 18.74; S, 14.30; Found: C, 56.24; Н, 3.60; N, 18.75; S, 2, 4] triazino [2,3-c] quinazolin-6-yl)thio]acetamide (5.2) Yield: Method А, 87.2%; M.p. 258-260°C; IR (cm -1 ): 3269, 3225, 3157, 3076, 2991, 2963, 2921, 2851, 1703, 1668, 1649, 1589, 1564, 1544, 1503, 1485, 1466, 1445, 1363, 1339, 1312, 1284, 1261, 1210, 1182, 1152, 1137, 1118, 1105, 1083, 1046, 1020, 1001, 989, 977, 940, 887, 873, 849, 809, 784, 773, 756, 692, 655, 615; 1 H-NMR (400 MHz) δ: 2.40 (s,
Cytotoxic activity against malignant human tumor cells
The primary anticancer assay was performed at the human tumor cell lines panel derived from nine neoplastic diseases, in accordance with the protocol of the Drug Evaluation Branch, National Cancer Institute, Bethesda [27] [28] [29] [30] . Tested compounds were added to the culture at a single concentration (10 −5 M) and the cultures were incubated for 48 h. End point determinations were made with a protein binding dye, sulforhodamine B (SRB). Results for each tested compound were reported as the percent of growth of the treated cells when compared to the untreated control cells. The percentage growth was evaluated spectrophotometrically versus controls not treated with the test agents. The cytotoxic and/or growth inhibitory effects of the most active selected compounds were tested in vitro against the full panel of about 60 human tumor cell lines at 10-fold dilutions of five concentrations ranging from 10 −4 to 10 −8 M. A 48-h continuous drug exposure protocol was followed and an SRB protein assay was used to estimate cell viability or growth. Using the seven absorbance measurements [time zero, (T z ), control growth in the absence of the drug (C), and test growth in the presence of the drug at the five concentration levels (T i )], the percentage growth was calculated at each of the drug concentrations levels. Percentage growth inhibition was calculated as:
[(T i − T z )/(C − T z )] × 100 for concentrations for which T i ≥ T z , [(T i − T z )]/T z ] × 100 for concentrations for which T i < T z .
Three dose response parameters were calculated for each compound. Growth inhibition of 50% (GI 50 ) was calculated from [(T i − T z )/(C − T z )] × 100 = 50, which is the drug concentration resulting in a 50% lower net protein increase in the treated cells (measured by SRB staining) as compared to the net protein increase seen in the control cells. The drug concentration resulting in total growth inhibition (TGI) was calculated from T i = T z . The LC 50 (concentration of the drug resulting in a 50% reduction in the measured protein at the end of the drug treatment as compared to that at the beginning) indicating a net loss of cells following treatment, was calculated from [(T i − T z )/T z ] ×100 = -50. Values were calculated for each of these three parameters if the level of activity was reached; however, if the effect was not reached or was exceeded, the value for that parameter was expressed as greater or less than the maximum or minimum concentration tested. The log GI 50 , log TGI, and log LC 50 were then determined, defined as the mean of the logs of the individual GI 50 , TGI, and LC 50 values. The lowest values were obtained with the most sensitive cell lines.
